Mauna Kea's Cellvizio Gen 3 receives approval in China

Mauna Kea Technologies has received approval from the National Medical Products Administration (NMPA) in China for its third-generation Cellvizio platform. This approval allows the device to be marketed for five years, until November 2030. The Cellvizio Gen 3 includes a full range of confocal probes and is not affected by the joint venture agreement with Tasly.

The rapidly growing Chinese market for interventional endoscopy represents a major opportunity for Mauna Kea, which is currently evaluating its market entry options. The company aims to make its technology accessible to Chinese hospitals to meet the increasing demand for precision diagnostics.

Sacha Loiseau, CEO of Mauna Kea, believes that this authorization strengthens the company's competitive position in China and could increase projected revenues.